Gliadel Wafer + Temozolomide
Phase 2UNKNOWN 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Newly Diagnosed Supratentorial Malignant Glioma
Conditions
Newly Diagnosed Supratentorial Malignant Glioma
Trial Timeline
Sep 1, 2002 → Apr 1, 2008
NCT ID
NCT00283543About Gliadel Wafer + Temozolomide
Gliadel Wafer + Temozolomide is a phase 2 stage product being developed by Eisai for Newly Diagnosed Supratentorial Malignant Glioma. The current trial status is unknown. This product is registered under clinical trial identifier NCT00283543. Target conditions include Newly Diagnosed Supratentorial Malignant Glioma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00283543 | Phase 2 | UNKNOWN |
Competing Products
18 competing products in Newly Diagnosed Supratentorial Malignant Glioma